ArticleJournal of clinical medicine2023

Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease.

Lutz B Jehn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.